12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Lexaria has completed its submission to the human research ethics committee ("HREC") for its planned addition of Study Arm 5 ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

"Adherence improves when treatment integrates easily into patients’ lives," explains Adam McBride, Eden’s CEO. Eden’s digital ...

Katz, M.D., of the John A. Moran Eye Center at University of Utah Health, saw a patient who experienced sudden painless vision loss after starting semaglutide. The patient stopped using the drug ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Can GLP-1 Meds Harm Your Eyes ... who were taking GLP-1s such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound). Seven of the nine patients developed a condition known as ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally ... compared to other antidiabetic drugs. 4 These observations were based on 100 million patient records ...

Past studies have found a potential link between semaglutide and the eye condition ... it’s important for researchers to continue to examine how GLP-1 medications might impact other areas ...

Are you a print subscriber? Activate your account. By Tim Nudd - 14 min 58 sec ago 2 hours 35 min ago By Parker Herren - 2 hours 48 min ago By Brian Bonilla - 2 hours 48 min ago By Jean-Paul ...

Like most drugs, Mounjaro can cause side effects. Hair loss was not a reported side effect of Mounjaro, but it was reported with other GLP-1 agonists. Mounjaro can cause side effects, such as ...

Now, diabetes specialists and cardiologists are among the specialists flocking to GLP-1 drugs to manage blood sugar and weight. In many ways, it's easier for physicians to access these drugs.

In a nutshell, they found that a person taking semaglutide was 1.45 times more likely to mention suicidal ideation compared to patients on dapagliflozin, metformin, or orlistat, rising to 4.45 ...